Member Info for 4PetesSake

http://www.investegate.co.uk/syqic-plc--syq-/rns/agm-statement/201407180700106754M/ StoneBroke, I assume that this is what you had been hoping for. It will now enable them to talk about some of these things at the AGM today.

Boak Stephen Squire Foste ris still very much associated with COMS, where he is also sales director. He has an outstanding 35-year commercial and management track record in large businesses in international IT and Telephony sales and until his recent retirement was Vice President Sales for Siemens in the UK and Northern Europe. His contacts and experience will be invaluable to a company such as VMP. With DB's big investment in VMP, Stephen will clearly know much about the company. However as mentioned at the COMS AGM last Friday, VMP is just an investment (albeit a very big one) for DB and he does NOT intend to join the board. However with Stephen joining VMP, DB will no doubt be kept up to date with how his investment is progressing.

2 weeks into July and still only one trade her, holders are holding and buyers are waiting.

A £13.2k buy and now a delayed £30k buy. I'd love to know what these buyers know.

This is so under the radar. Only one trade this month - Wow. It will not always be this way.

Decent sized buys from 2 more directors suggest that they are confident about the prospects. Perhaps there is still some life in the old dog.

If Nick can keep the SP between 9-11p for a few weeks and then buy lots more in a placing at about 5-6p I reckon his last director buy will have been worth the minimal outlay of £10k. That will strengthen the balance sheet and help his average. Re COMS - One incorrect figure in the results hardly means thy have iffy account issues. The selling was overdone and recovery will come soon. I think it is more that likely that something significant will come out before the AGM.

High Mate, Nice to see you posting a bit again. how are things with you? Is you email address still the same (the Yahoo one). It does look promising here and I am watching it closely and will certainly invest here very soon.

Korg Your CEO only bought £10k worth and that hasn't even doubled his initial holding. If you think that is a vote of confidence from the boss then you are the amateur, which is the correct spelling of the word. Mind the spike.

Jolly, not sure what you mean with CCE I sold those months ago to buy VMP. As for COMS, that will recover and any day now I will be topping up. Well done on your profit here, selling some or all on a spike is always a smart move.

Sorry to give you a fright with that £ sign. My mistake. Another nice 1.46m shares bought to close today. The time must be getting near.

Extra cash was always going to be needed and 4p is about the right price after the recent sentiment driven bounce. Today's fall was always going to happen after the announcement.

http://www.investegate.co.uk/outsourcery-plc--out-/rns/capital-markets-day-trading-update/201406270700076922K/ Ka Ching I agree, a very mixed bag and a fair summary of the RNS. Future potential looks good for those who are looking beyond h2 in 2015, by which time they hope to reach cash flow break even. In the shorter term the it is good to see that they have identified areas where they can reduce costs by £1m a year albeit these saving will only commence from the beginning of the next financial year. For me the biggest concern is around the comments on funding namely: The financing options include, but are not limited to: · Revision, amendment and/or extension to existing debt facilities; and/or · Investment by one or more of the Group's strategic partners; and/or · Raising of additional equity finance The Board will update the market on its progress in investigating these options during the course of July. This cash flow issue is likely to be a major concern in the short term. A mixed bag indeed!

Jolly You will be the one with egg on your face when a placing is announced.

Oh dear, perhaps a placing to raise some cash will be next.

Venn Life Sciences (AIM: VENN), a growing Clinical Research Organisation providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, will hold its Annual General Meeting today at 3pm at 4 Lombard Street, London EC3V 9HD. In advance of the formal proceedings of the meeting the Chairman, David Evans, will make the following statement: I am pleased to report that we continue to make good progress towards our goal of becoming a leading mid-sized European CRO with an expertise in managing complex multi-country clinical trials. As I mentioned in our results statement we have made significant progress in the scale and quality of our potential deal flow pipeline, with strong leads on a number of higher value Enterprise Level deals. Last month we announced the securing of a particularly significant clinical trials management agreement for an orphan drug for the rare acute disease market. This multi-site agreement is worth over €3m and will run for over a year and a half, covering seven European countries as well as a number of US sites. This contract win endorses our change of focus from small single country projects to larger multi-centred projects and we hope to update shareholders on further project wins as they happen. In addition, I am pleased with the progress made so far by Innovenn, our innovation division, since the acquisition of the anti-acne and living skin equivalent technology of Evocutis. We announced earlier in the month the grant of our first skin science patent by the European Patent Office and we have commenced commercial partnership discussions regarding Labskin which we expect to lead to additional revenue flows later this year. We remain confident for the future and continue to expect to see significant gains in revenue in the second half of 2014.

You got your wish and BB's are now bears.

Some big money is being invested here, someone does not buy 3m of these on a whim and a prayer. One of these days, that RNS with the Plan will be released.

That is now 2 days in a row where a 5 figure buy has gone through after the end of trading. The only similar recent big buys were on 27th May, one of which was a director buy. In my opinion, people in the know are filling their boots at a bargain price.

It is indeed loss making at the moment, like the majority of other AIM companies. R&D costs always seem heavy until contracts are won and products are brought to the market. They key question is surely, "What they are doing to turn the company around to make it profitable." Costs have been high, as Venn invested heavily in 2013 in preparing the business for a step change in the size and complexity of contracts undertaken. The recent 3m Euro contract win, the first part of the current 12m Euro pipeline, represents a significant endorsement of their investment strategy since IPO. This contract ALONE is worth more than all their revenues from last year. Should they be successful with the rest of the pipeline then profitability is on the way. They have now moved their business focus from small single country projects to larger multicentred projects and expect to cement this progress with additional project wins in the coming months. They have also made some very shrewd acquisitions at knock down prices such as the intellectual property from Evocutis. Since that acquisition, tremendous progress has been made in bringing the anti-acne and living skin equivalent technology to the marketplace. So do we invest here whilst the company is still making a loss and the SP is low, or wait until it is profitable and the SP is higher??? A director who knows the potential has just put in £50k+ of his own money and he clearly know a lot more about the business that we do.